In breast cancer, amplification of MYC is consistently observed in aggressive forms of
disease and correlates with poor prognosis and distant metastases. However, to date, a
systematic analysis of MYC amplification in metastatic breast cancers has not been reported.
Specifically, whether the MYC amplification status may change in metastases in comparison
to the corresponding primary breast tumor, and potential variability among different
metastases within the same patient have also not been assessed. We generated single …